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Abstract
Clinical trial allocation in multinational pharmaceutical companies includes
country selection and site selection. With emphasis on site selection, the overall
aim of this study was to examine which factors pharmaceutical companies value
most when allocating clinical trials. The specific aims were (1) to identify key
decision makers during country and site selection, respectively, (2) to evaluate
by which parameters subsidiaries are primarily assessed by headquarters with
regard to conducting clinical trials, and (3) to evaluate which site-related quali-
ties companies value most when selecting trial sites. Eleven semistructured
interviews were conducted among employees engaged in trial allocation at 11
pharmaceutical companies. The interviews were analyzed by deductive content
analysis, which included coding of data to a categorization matrix containing
categories of site-related qualities. The results suggest that headquarters and
regional departments are key decision makers during country selection, whereas
subsidiaries decide on site selection. Study participants argued that headquarters
primarily value timely patient recruitment and quality of data when assessing
subsidiaries. The site-related qualities most commonly emphasized during inter-
views were study population availability, timely patient recruitment, resources
at the site, and site personnel’s interest and commitment. Costs of running the
trials were described as less important. Site personnel experience in conducting
trials was described as valuable but not imperative. In conclusion, multinational
pharmaceutical companies consider recruitment-related factors as crucial when
allocating clinical trials. Quality of data and site personnel’s interest and com-
mitment are also essential, whereas costs seem less important. While valued, site
personnel experience in conducting clinical trials is not imperative.
Introduction
Clinical trial allocation in multinational pharmaceutical
companies is a complex process determined by multiple
factors. The process contains two fundamental steps.
First, clinical trials are allocated to different geographic
regions during a country selection process led by the
headquarters of the company. Subsequently, a site selec-
tion process is conducted during which the subsidiaries
of the regions involved contact potential trial sites and
make an evaluation of these sites. Based on this
evaluation, the company decides which trial sites it pre-
fers to collaborate with. Country selection depends on
factors such as patient availability, national treatment
practices, and sales potential of the drug, but also on
the performance of subsidiaries and trial sites in prior
trials. Therefore, the subsidiaries of a company are to
some extent internally competing to attract clinical tri-
als to their region.
Many national governments and trial sites are inter-
ested in conducting industry-sponsored clinical trials, as
these are often considered beneficial for the patients
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included, the trial sites involved, and the country as a
whole. However, knowledge of which factors pharmaceu-
tical companies values most when allocating clinical trials
is sparse. To our knowledge, only one published study
has investigated factors that influence trial allocation in
Europe (Gehring et al. 2013). A better understanding of
the pharmaceutical industries’ allocation of clinical trials
is essential if governments and trial sites are to attract
and retain more industry-sponsored clinical trials.
Accordingly, with emphasis on site selection, the
overall aim of this study is to examine which factors
pharmaceutical companies value most when allocating
clinical trials. The specific aims are (1) to identify
which departments internally in pharmaceutical compa-
nies, and possibly externally, are key decision makers
during country and site selection, respectively, (2) to
evaluate by which parameters subsidiaries are primarily
assessed by headquarters with regard to conducting
clinical trials, and (3) to evaluate which site-related
qualities companies value most when selecting trial
sites.
Materials and Methods
Design, setting, and participants
Eleven semistructured interviews were conducted among
employees engaged in clinical trial allocation at 11 multi-
national pharmaceutical companies (Appendix 1).
The following inclusion criteria were set:
1 The participants should be working with allocation of
clinical trials at a multinational pharmaceutical com-
pany.
2 The company should be a multinational pharmaceuti-
cal company within the top 25 in terms of economic
turnover (PM Live 2016).
3 The company should have a Danish subsidiary running
clinical trials in Denmark.
We recruited the participants through the Danish
Association of the Pharmaceutical Industry (LIF). Par-
ticipants were included consecutively. In total, 16 eligi-
ble participants were contacted via an email describing
the aim of the project. Five of these declined to partici-
pate. Ten of the included participants were employed
at the Danish subsidiary of their company at the clini-
cal operations department, whereas one was employed
at the European regional clinical operations department.
All participants had at least 5 years of experience with
clinical trial allocation. The strategic and operational
work patterns within the companies were unknown to
the authors. Likewise, the participants’ role in the com-
pany and perceptions regarding trial allocation were
unknown.
Data collection
From 31st March to 13th May 2016, 11 semistruc-
tured in-depth interviews were conducted in Danish
using an interview guide (Appendix 2 (English),
Appendix 3 (Danish)). The first part of the interviews
was focused on the company’s internal organization
with emphasis on decision makers during trial alloca-
tion. The second part was focused on the site selec-
tion process, emphasizing site-related qualities. The
participants were encouraged to speak freely, and in
relation to the semistructured style of the interview,
the interview guide was not followed strictly but
served as a guiding tool. The guide was modified after
the first and fourth interview. The interview guide
and the citations presented were translated by a native
speaker of English.
Seven of the interviews were conducted face-to-face
at the companies’ Danish subsidiaries, whereas four of
the interviews, for practical reasons, were conducted by
telephone. The interviews lasted between 1 h and
15 min and 1 h and 45 min and were conducted, tran-
scribed, and analyzed by the first author (TD). The
seven face-to-face interviews were digitally, audio-
recorded. Interview passages concerning the evaluation
of trial sites were transcribed verbatim, whereas the rest
was transcribed nonverbatim. The four telephone inter-
views were not audio-recorded. During the interviews,
as many notes as possible were made by the interviewer
(TD). The text was elaborated on and corrected in rela-
tion to the specific questions asked immediately after
the interviews. Subsequently, the participants were con-
tacted by email or phone to elaborate on their answers,
if necessary. These responses were included in the data
analysis. By Danish law, ethics approval was not
required for this study.
Data analysis
The interviews were analyzed using deductive content
analysis as described by Elo and Kyngäs (2008). We
decided to analyze only the manifest content of the inter-
views (Graneheim and Lundman 2004). A categorization
matrix was created before the interviews were conducted.
It contained 6 categories and 14 subcategories of
site-related qualities by which pharmaceutical companies
theoretically evaluate trial sites during site selection. The
categories were modified from categories made by
Gehring et al. (2013) and Harper and Zuckerman (2006).
One subcategory (site personnel’s mindset) was added dur-
ing the data analysis (Fig. 1).
The data analysis contained three main phases:
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Overview
The transcripts were read several times to obtain an over-
all impression of the content.
Analysis of site-related qualities
The categorization matrix was used as a lens during the
individual reading of the transcripts. Meaning units were
defined in reference to Graneheim and Lundman (2004)
and were interpreted with regard to the context of the
specific interview. The meaning units were color coded in
relation to the corresponding subcategory of the catego-
rization matrix. Subsequently, all meaning units that did
not fit the categorization matrix were interpreted together
in an inductive manner to examine if any possible cate-
gories were overlooked. The subcategory site personnel’s
mindset was added to the categorization matrix; eight par-
ticipants emphasized site-related qualities that could be
summarized by this subcategory exclusively. Finally, state-
ments related to each subcategory were reviewed together
across all interviews in order to evaluate each subcategory
independently. The coding of data is exemplified in
Figure 2.
Analysis of the remaining content
The remaining content was interpreted without coding;
however, the interviews were still systematically
reviewed to ensure that all relevant statements were
included.
Results
Decision makers during clinical trial
allocation
The key decision maker during country selection was the
headquarters, in some of the companies in collaboration
with regional departments. The subsidiaries were not
decision makers in this process, but the participants sta-
ted that the subsidiaries influence country selection by
different means such as giving feedback to the headquar-
ters in feasibility questionnaires, introducing the head-
quarters to potential trial sites, and aiming for key
opinion leaders at advisory boards. During site selection,
the key decision makers were the subsidiaries. In most of
the companies, the subsidiaries solely decided which trial
sites to include, although the headquarters formally had
to approve the selected sites. Nine companies outsourced
clinical trials to clinical research organizations (CROs). In
fully outsourced clinical trials, the CROs were decision
makers during country selection in collaboration with the
headquarters and regional departments. Generally, the
CROs and the subsidiaries collaborated on deciding which
trial sites to include during site selection.
Assessment of the subsidiaries
All of the participants believed that timely patient recruit-
ment is the most or one of the most important factors by
which the headquarters evaluate the subsidiaries. Seven
participants also mentioned quality of data as essential.
Figure 1. Categorization matrix containing categories of site-related qualities by which pharmaceutical companies theoretically evaluate clinical
trial sites during site selection.
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However, two participants disagreed that the headquarters
highly values quality. All participants expressed that costs
of running a clinical trial are not as important to the
headquarters as other factors.
It was emphasized that the Danish/Nordic subsidiaries
have to keep demonstrating a successful patient recruit-
ment to ensure allocation of future trials to the country;
small countries are not automatically assigned trials and
they risk being deselected if patient recruitment is insuffi-
cient. In contrast, some argued that large countries are
often selected regardless of their prior recruitment perfor-
mance due to other factors such as sales potential of the
drug.
Provided that the data are ok, that the quality is sufficient,
then that is what we are assessed by; do we deliver what we
promised to deliver by the agreed upon deadline. If we do
so, we can be sure to be offered lots of trials (. . .) We are
also assessed on whether we make database logs, queries,
etc. on time, but overall, the graphs we are presented for
are regarding recruitment. That is why I say that I want to
know if my sites can deliver the number of patients they
promise, because it matters at the other end.’ (Interview 1).
If we have the patients, then if it ends up costing 100,000
more in total or whatever it might be, it is not what they
are looking at. The U.S. is already more expensive but they
are still running trials. So that is not the most important
thing, so to speak.’ (Interview 2).
Evaluation of site-related qualities
Overall, the site-related qualities most commonly empha-
sized during interviews were patient population availabil-
ity, timely patient recruitment, resources at the site, and
site personnel’s interest and commitment (Fig. 1). These
were emphasized more than, for example, experience,
quality of data, and costs. Study participants argued that
site selection is based on a weighing of benefits and disad-
vantages in each case, taking also into account the num-
ber of sites available. Furthermore, the qualities that are
the most important vary by type of protocol, phase, and
therapeutic area. Two participants noted that when a trial
demands both blinded and unblinded personnel, a high
level of resources at the site is required. Another
explained that experience within the therapeutic field is
often essential in an early phase II trial, as the investigator
has to be good at distinguishing side effects from symp-
toms of the disease.
Patient recruitment
All of the participants spontaneously mentioned that
patient population availability and timely patient recruit-
ment are crucial when selecting trial sites. These qualities
were repeatedly emphasized. Study participants all
described how they aim to get a valid estimation of the
number of patients the site personnel believe to be able
Figure 2. An example of coding of data to the categorization matrix1: 1The categorization matrix is displayed in Figure 1.
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to recruit, as this is usually crucial to a successful patient
recruitment and therefore a high priority to the company.
The importance of a rapid startup time was also empha-
sized.
It is a lot of the same things [we emphasize] as when we
select the countries. It is how many patients we can recruit
per site per month. And within that discussion we also
cover how quickly we can begin, because the more months
they have available for enrolment, the better the chance is
that they will reach their target in regard to the number of
patients they committed to. So those are the most impor-
tant factors. (Interview 5).
It is first and foremost the quality as well as their ability to
prove that they can deliver the patients; that they have
really looked at their database and can tell us whether they
have the patients and that they are quick; that they already
have them lined up before we start so that they can take a
patient as soon as we are ready.’ ‘So what I am hearing you
say is that the startup phase matters?’ ‘Yes, it matters a lot.
And of course that they deliver the number of patients they
promised. That also means everything.’ (Interview 3).
Quality
Only half of the participants spontaneously mentioned
quality-related aspects. However, when asked, the partici-
pants stated that they find a high level of quality indis-
pensable. One said that they would never compromise on
quality, and another argued that she would rather have
data of high quality from a few patients than data of low
quality from a large number of patients, as some might
have to be removed from the dataset subsequently. It was
stated that if there have been findings at prior audits or
inspections at a site, the company will usually address this
by closely monitoring and supporting the site in future
trials.
We really work a lot on the quality, and it is our job to go
out and help to ensure that the quality is acceptable, but if
we have sites that fundamentally do not understand their
responsibility - that the data and patient security are para-
mount - then that makes our job very difficult and in the
end, we have to let a site like that go.(Interview 6).
Costs
Generally, costs at the trial site were described as less
important than other factors. Eight participants conceded
that the headquarters usually approve the selected sites
regardless of the costs at the site. However, two partici-
pants argued that a rise in costs at Danish sites could be
problematic, as the headquarters consequently might
choose to allocate fewer trials to the country.
When you are at a site, how much does the price mean to
you, when you are evaluating them prior to a possible collab-
oration? Well I would say that as long as we can (interrupts
herself). The price just needs to be within what is OK from
a compliance point of view. It should not be so high that
we can get accused of overpaying, so we have a grand plan
that we work around. I think most within the industry use
these grand plans (. . .) Have you experienced that Global
[the headquarters] challenges the price that you have on a
site? Have you experienced that? Only if it is over what the
grand plan says, and then I am asked to justify why the
price is acceptable. If you do, do you usually get an OK?
Yes. Yes, if you can provide arguments for it. (Interview 8).
Set up at the site
All participants mentioned that they thoroughly evaluate
resources at the site as these influence patient recruitment
during a trial considerably. Five participants argued that
they find it important to talk to the operational site per-
sonnel (study coordinators, study nurses, etc.) as they, in
contrast to the investigator, know if the study is feasible
and the resources available.
‘And I would say that the second most important factor is
that they have the resources it requires; the employee-related
resources they have on the site. That they have enough to
complete the study within the timelines we have set up. And
I would say that all the more practical things concerning
equipment, room facilities, storing of drugs, those are more
formalities. They are never a problem.’ (Interview 5).
Site personnel’s attitude toward running a clinical
trial
The importance of a high level of interest and commitment
among site personnel were emphasized repeatedly. Further,
all participants confirmed that they find this quality crucial
for a trial to succeed. One participant stressed that site per-
sonnel cannot convince patients to participate in a trial if
they are not enthusiastic about the trial themselves. The need
for site personnel to have the right mindset was also empha-
sized. It was stated that site personnel need to ‘know what
the role of being principal investigator entails’ (Interview 1),
‘not be dismissive of documentation requirements’ (Inter-
view 3), and ‘understand how time-consuming it is’ (Inter-
view 11).
The interest and the resources are very important. We put
a lot of effort into aligning expectations. It is, after all, a
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collaboration. Both partners have to find it interesting (. . .)
We have a thorough dialogue with the site about what it is
about and what our expectations are. Is this really some-
thing that the site wants to participate in? (Interview 9).
Experience
Site personnel experience in conducting clinical trials was
referred to as valuable but not imperative. Seven partici-
pants argued that a lack of experience does not exclude a
site from participation in clinical trials as the company
can compensate by allocating more resources to training
and monitoring at the site. However, it was also argued
that experience is very important in early phase trials as
these contain a circumstantial number of procedures that
need to be completed within a narrow time limit; limited
experience is more acceptable in phase III and IV clinical
trials. Depending on the kind of trial and whether the
subsidiary has got the resources, the company will select
or deselect inexperienced sites.
‘If you have a new site that is untrained, is that something
that will exclude them from participation?’ ‘No. No, it is not.
We just would not include only brand new sites for a clini-
cal trial. But we would really like to expand to have, for
example, one or two or whatever would be possible,
because it requires significantly more resources. Because
they need training. That is the issue. That that is also the
case for them. It is also on their side, right?’ ‘But what I
am hearing you say is that it is not like it is out of the ques-
tion that they can participate?’ ‘No, no not at all. On the
contrary, we really want to expand too, because it is also a
way to expand our research in Denmark and access to the
patients.’ (Interview 9).
Having a key opinion leader associated with the site
was not highly valued. Many argued that the subsidiaries
do not include a site because of a specific key opinion
leader if this can compromise patient recruitment. How-
ever, all participants conceded that they sometimes expe-
rience disagreement between the marketing department or
the headquarters and the clinical operations department
as whether or not to include a site because of an impor-
tant key opinion leader. Some argued that key opinion
leaders presumably play a greater role in the large
countries.
Discussion
The main findings of this study suggest that recruitment-
related factors and quality of data are essential to
multinational pharmaceutical companies when allocating
clinical trials, whereas costs of running trials seem less
important. Furthermore, site personnel’s interest and
commitment are apparently imperative, whereas experi-
ence in conducting clinical trials is not.
Patient population availability and timely patient
recruitment at a site were described as crucial to pharma-
ceutical companies regardless of the type of clinical trial.
In addition, all study participants believed that the head-
quarters of their company find timely patient recruitment
essential when evaluating the subsidiaries. It is expected
that recruitment-related factors are among the most
important factors during trial allocation, as a successful
recruitment is crucial to a successful clinical trial. Fur-
thermore, recruitment is often one of the most challeng-
ing parts of running a trial, and in nearly 80% of clinical
trials, enrolment timelines are not met (Kremidas 2011).
Moreover, pharmaceutical companies have only limited
influence on the recruitment once a trial is running; they
basically depend on site personnel recruiting the patients.
In contrast, it is easier for the companies to influence
other factors. As the participants of this study expressed,
the companies can somewhat ensure sufficient data qual-
ity and compensate for a lack of experience among site
personnel by allocating extra resources to monitoring and
training at the site.
The key decision maker during country selection is the
headquarters. Therefore, trial sites indirectly influence
country selection as they basically control patient recruit-
ment, which is highly valued by the headquarters. Site
personnel should be aware of this and aim to gain a suc-
cessful recruitment not just for the benefit of the trial site
but for the benefit of the country as a whole. However, it
is plausible that the indispensability of timely patient
recruitment primarily applies to small countries, as large
countries may benefit from other factors. This is sup-
ported by the fact that the United States is involved in
numerous clinical trials despite investigators in the United
States enrolling only two-thirds as many subjects as inves-
tigators in the rest of the world (English et al. 2010).
The costs of running clinical trials seemed less impor-
tant than other factors during both country and site selec-
tion. This corresponds to the findings by Industry
Standard Reports in 2009. They found that among 362
clinical trials stakeholders, 80% preferred to reach enrol-
ment goals 10% more quickly, rather than cutting costs
by 20% (Gossen 2011). The questionnaire study made by
Gehring et al. (2013) also found cost factors to be less
important than other factors during both country and site
selection. Respondents were asked to divide 100 points
across four different factors impacting trial site selection
(investigator, hospital/unit, environmental, and cost fac-
tors). Among the 341 clinical trials stakeholders who
responded, cost factors were generally rated the lowest
number of points. Moreover, costs of running trials were
2017 | Vol. 5 | Iss. 3 | e00317
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significantly less important than the pool of eligible
patients in the region, speed of approvals, and presence
of disease management networks (Gehring et al. 2013).
Data from this study indicate that inexperienced trial
sites should not feel excluded from engaging in clinical
trials. Seemingly, a trial site having enthusiastic and
committed site personnel will be selected for phase III
and IV trials despite a lack of experience, if the sub-
sidiary has the resources to support the site sufficiently.
Generally, pharmaceutical companies seem to highly
value the right mindset and interest and commitment
among site personnel when selecting trial sites. Hospital
managements and trial sites that wish to attract more
industry-sponsored trials might benefit from focusing
more on these nonmeasurable qualities. Firstly, it seems
beneficial to have easily reachable site personnel and a
quick response time when communicating with the com-
panies. Secondly, before committing to a trial, hospital
management teams and investigators should prioritize
consulting the operational site personnel to assess their
immediate attitude toward running the trial. Moreover,
it might be beneficial to include nonmeasurable qualities
such as reachability and commitment in advertising
material alongside traditional factors such as recruitment
rates in prior trials.
Strengths and limitations
All interviews were conducted and transcribed by the
same researcher. We believe that this is a strength, as the
interviews in this manner were conducted in a uniform
matter and the interpretation was aligned. Only one
author made the data analysis. However, we believe that
this is not a considerable limitation as a stringent data
analysis was used, and the interviews did not require
interpretation with a high level of abstraction. The study
has other noteworthy limitations though. Most impor-
tantly, data saturation was not met as it was difficult to
comprehensively cover the study aims. Secondly, the par-
ticipants constituted a homogenous group. Thus, the
gained information is limited to this group of clinical trial
stakeholders. One might argue that the results are only
representative for Danish subsidiaries. However, all partic-
ipants believed that the subsidiaries of different countries
basically evaluate trial sites in the same way, including the
same parameters.
Conclusions and future studies
This study found that multinational pharmaceutical com-
panies consider recruitment-related factors as crucial
when allocating clinical trials. Quality of data and site
personnel’s interest and commitment are also essential,
whereas costs of running the trials seem less important.
While valued, site personnel experience in conducting
clinical trials is not imperative.
Numerous aspects of this area are still incompletely
understood. Future studies should further investigate
what influences trial site selection, including how the
importance of each site-related quality varies by type of
protocol, trial phase, and therapeutic area. In addition, it
would be interesting to examine potential differences in
site selection between countries. Moreover, knowledge of
which factors pharmaceutical companies emphasize when
allocating clinical trials to specific countries is still sparse.
Finally, it would be relevant to examine the role of CROs
during clinical trial allocation.
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Appendix 1. List of the multinational
pharmaceutical companies at which
the 11 participants of the study were
employed:
AbbVie
AstraZeneca
Biogen
Bristol-Myers Squibb
Eli Lilly
Merck Sharp & Dohme (MSD)
Novartis
Novo Nordisk
Pfizer
Roche
Sanofi
Appendix 2. Interview guide in English:
Part 1
The first questions attempt to identify key decision-makers
during allocation of clinical trials that your company spon-
sors. The aim is to examine which departments internally in
the company, and possibly externally, are decision-makers
during allocation of clinical trials on a country and site
level. Moreover, the aim is to examine if decision-makers
differ depending on which trial phase and therapeutic area
the clinical trials concern.
Would you please start by telling a little bit about who
makes the decisions when your company allocates clinical
trials?
Can you elaborate on which role the subsidiaries and
headquarters respectively play during the allocation process?
Does who makes the country- and site selection differ
depending on the kind of clinical trial?
Is the allocation process generally the same regardless
of the specific phase and therapeutic area?
By which parameters does your headquarters assess the
subsidiaries before and after conducting a clinical trial?
Does your company sometimes outsource decisions
regarding country and site selection to others - for exam-
ple CROs?
When outsourcing clinical trials, is it typically clinical
trials within certain phases or therapeutic areas that are
being outsourced?
When outsourcing, is it both country selection and site
selection that are being outsourced?
Part 2
The following questions address how your company evalu-
ates a trial site prior to a potential collaboration including
which factors are essential to whether or not your company
chooses to engage in such a partnership. The aims are to
explore which parameters your company values most when
evaluating potential trial sites and on which basis the evalu-
ation is done.
Does the company have a decision model or unified
guidelines which it uses during site selection?
If yes: Does the company have unified guidelines for
the different subsidiaries to use?
If no: On what basis is site selection then done?
Do you experience the site selection process as similar
from case to case or as somewhat more unstructured?
Is the site selection process the same regardless of trial
phase and therapeutic area?
What do you and your colleagues take into account
when assessing the benefits and drawbacks of a clinical
trial site?
Can you give an example of parameters that are essen-
tial for some types of clinical trials, but not essential for
other types of clinical trials?
Can you elaborate on which parameters you value the
most?
Are there certain circumstances or parameters which
are almost always important?
If you are assessing a site which your company has not
cooperated with before, which parameters do you particu-
larly value?
What would you prefer that the sites you cooperate
with were better at?
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How often does it happen that a site with which your
company wishes to cooperate on a clinical trial declines
the offer?
Are data regarding the patient recruitment rate in prior
trials important to you when assessing a site? Do you sys-
tematically ask about this information during the feasibil-
ity process or at the site selection visit?
When performing site selection, do you always ask
about deviations at prior inspections at the site?
How often do you think your company chooses to
cooperate with a trial site that does not perform satisfac-
torily because you have to take specific organizations or
persons such as key opinion leaders into account?
Do you think that the things we have discussed apply
to the company as a whole or only to your department?
Do you think that other subsidiaries at your company
evaluate trial sites in the same way as you, including the
same parameters?
Is there anything else you would like to add?
Appendix 3. Interview guide in Danish:
Del 1
De første spørgsmal handler om, hvem der tager beslut-
ninger omkring placeringen af de kliniske forsøg, som din
virksomhed er sponsor for. Formalet er at belyse, hvem der
internt i virksomheden og evt. eksternt star for placeringen
af virksomhedens kliniske forsøg pa landebasis og pa siteba-
sis. Derudover er formalet at belyse, om der er forskel pa,
hvem der star for placeringen af de kliniske forsøg, alt efter
hvilken fase og terapeutisk omrade, der er tale om.
Vil du starte med at fortælle lidt om, hvem der tager
beslutningerne omkring placeringen af kliniske forsøg i
din virksomhed?
Kan du uddybe, hvilken rolle henholdsvis datterselsk-
aberne og hovedkvarteret har ved placeringen af forsøg?
Er det forskelligt, hvem der udfører lande- og site
selektion, afhængig af hvilken type forsøg der er tale om?
Er processen ved tildeling af forsøg overordnet den
samme uanset fase og terapeutisk omrade?
Hvilke parametre bedømmer hovedkvarteret jer dat-
terselskaber pa forud for og efter et klinisk forsøg?
Outsourcer virksomheden nogen gange beslutninger
om lande- og site selektion til andre, f.eks. CROer?
Outsourcer I typisk indenfor bestemte faser og/eller
bestemte terapeutiske omrader?
Er det i sa fald bade lande- og site-selektion som out-
sources?
Del 2
De næste spørgsmal handler om, hvordan I som virksomhed
vurderer et site forud for et eventuelt samarbejde, og hvilke
faktorer der er afgørende for, om I vælger at indga i et
sadan samarbejde. Formalet er at belyse, hvilke faktorer I
som virksomhed vægter højest, nar I vurderer potentielle
sites, og pa hvilket grundlag vurderingen sker.
Har I i virksomheden en beslutningsmodel eller fælles
retningslinjer, som I benytter ved site selektion?
Hvis ja: Er der fælles retningslinjer for de forskellige
datterselskaber?
Hvis nej: Pa hvilket grundlag sker site selektion sa?
Oplever du site selektion-processen som ensartet fra
gang til gang eller som mere ustruktureret?
Er site selektion processen den samme uanset fase og
terapeutisk omrade?
Hvad noterer I jer, nar I skal vurdere fordele og ulem-
per ved et site?
Kan du give eksempler pa faktorer, som har stor betyd-
ning ved nogle typer forsøg, men mindre betydning ved
andre typer forsøg?
Kan du uddybe, hvad I vægter højest?
Er der omstændigheder eller faktorer, som næsten altid
spiller en rolle?
Hvis der er tale om et site, I ikke kender fra tidligere,
hvilke faktorer lægger I sa særlig vægt pa?
Hvis du kunne vælge, hvad ville du sa helst have, at de
sites I arbejder sammen med blev bedre til?
Hvor ofte sker det, at et site som I ønsker at arbejde
sammen med i forbindelse med et klinisk forsøg, takker
nej til samarbejdet?
Er data fra site vedrørende patientrekruttering-
shastighed og -succesrate i tidligere forsøg vigtige for jer
ved vurderingen af sites? Spørger I systematisk til disse
oplysninger ved feasibility eller site selection visit?
Spørger I altid til deviations ved tidligere inspektioner
ved site selektion?
Hvor ofte vurderer du, at I i virksomheden vælger at
samarbejde med et site, som ikke leverer godt, fordi I skal
tage hensyn til specifikke organisationer eller personer sa
som key opinion leaders?
Vurderer du, at de ting som du har beskrevet, kan siges
at være gældende for hele virksomheden eller kun den
enhed, du sidder i?
Vurderer du, at de andre datterselskaber vurderer sites
pa samme made som jer og lægger vægt pa de samme
faktorer?
Er der yderligere, du vil fremhæve eller tilføje?
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